CDK7 inhibition has been demonstrated to disrupt cell cycle progression and to induce DNA replication stress and genome instability in SCLC, being another candidate for targeted therapy in SCLC (Zhang et al, 2017). Here, CDK7 is linked to small cell lung carcinoma.